InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (3 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
3
T+90 hit rate
0%
T+90 mean return
-26.9%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Valantine Hannah, Director. Officer active across 3 companies, notably CareDx, Inc.. Aggregated, 25 disclosures have been recorded. Split: 3 buys · 3 sells. Total volume traded: €66k. History available since 1 July 2021. The latest transaction was disclosed on 6 March 2025 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations25 total
3,990 sharesCommon StockSEC:0001470831-26-000635:0
2,808 sharesCommon StockSEC:0001470831-26-000635:1
2,808 sharesCommon StockSEC:0001470831-26-000635:2
2,196 sharesCommon StockSEC:0001470831-26-000635:3
9,795 sharesCommon StockSEC:0001855608-26-000003:0
12,103 sharesCommon StockSEC:0001855608-26-000003:1
12,875 shares@ US$16.7556.0% of flowCommon StockSEC:0000950170-25-036420:0
22,821 shares0Common StockSEC:0001299130-24-000156:0
10,570 shares0Common StockSEC:0000950170-24-074950:0
2,915 shares@ US$8.456.4% of flowCommon StockSEC:0000950170-24-017081:0
1,891 shares@ US$13.186.2% of flowCommon StockSEC:0000950170-24-014523:0
Ideal exit: 24 Sept 2022 (T+270)
2,915 shares@ US$8.456.3% of flowCommon StockSEC:0000950170-24-005380:0
2,915 shares@ US$8.456.3% of flowCommon StockSEC:0001209191-23-059101:0
2,915 shares@ US$8.456.3% of flowCommon StockSEC:0001209191-23-055717:0
18,844 shares0Common StockSEC:0001217234-23-000131:0
676 shares0Common StockSEC:0001217234-23-000008:0
422 shares0Common StockSEC:0001217234-22-000174:0
325 shares0Common StockSEC:0001217234-22-000139:0
4,863 shares0Common StockSEC:0001217234-22-000123:0
1,764 shares@ US$14.236.2% of flowCommon StockSEC:0000899243-22-000180
Ideal exit: 25 Sept 2022 (T+270)
1,764 shares@ US$14.230.0001% mcap50.0% of flowCommon StockSEC:0000899243-22-000180:0
Ideal exit: 25 Sept 2022 (T+270)
131 shares0Common StockSEC:0001217234-21-000221
131 shares0Common StockSEC:0001217234-21-000221:0
1,630 shares0Common StockSEC:0001217234-21-000160
1,630 shares0Common StockSEC:0001217234-21-000160:0
25 of 25 declarations
About Valantine Hannah
Hannah Valantine is a Director at CareDx, Inc. and BridgeBio Pharma, Inc. In these roles, she participates in the governance of the companies and strategic decision-making. Valantine brings her expertise and industry knowledge, which is essential for guiding growth and innovation initiatives. Her commitment to operational excellence is beneficial for both companies.
